Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new windowYouTube page opens in new window
investorenquiries@pharmaust.com+61 3 9692 7222
PharmAust (PAA)
Cancer Therapeutics Research
PharmAust (PAA)
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT

Daily Archives: 01/01/2023

Top 20 Shareholders December 2022

Financial Reports 2018, News & Announcements 2018, Top 20 ShareholdersBy PharmAust01/01/2023

Top_Holders_Report DEC

MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER

Twitter
YouTube

PharmAust Follow

PharmAust is a clinical-stage biotech company focused on repurposing monepantel (MPL) for human neurodegenerative diseases ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
3 Sep

📢 PharmAust is thrilled to share an exclusive interview with Dr. Michael Thurn ahead of our participation at the Spark+ Australian Equities Day in Singapore on Sept 20!
🔗 Watch the full interview & register:

Reply on Twitter 1830771209098985878 Retweet on Twitter 1830771209098985878 Like on Twitter 1830771209098985878 Twitter 1830771209098985878
pharmaust PharmAust @pharmaust ·
29 Aug

Exciting to see The Australian feature Pharmaust in an article about our recent Morgans coverage! 🚀 The potential upside for monepantel is gaining recognition. Check out the full story in The Australian: https://www.theaustralian.com.au/business/stockhead/content/morgans-sees-big-upside-for-pharmaust-if-monepantel-succeeds/news-story/56479301954b8469cab98c69f755f4ca #Pharmaust #Biotech #ALS #TheAustralian

Reply on Twitter 1828998188088582299 Retweet on Twitter 1828998188088582299 1 Like on Twitter 1828998188088582299 7 Twitter 1828998188088582299
pharmaust PharmAust @pharmaust ·
28 Aug

Excited to see Dr. Susan Mathers present the promising Phase 1 results of monepantel in ALS patients at the MND Research Symposium in Melbourne. A crucial step forward in improving lives worldwide! 🌍🔬 #ALS #MND #Research #Pharmaust

Reply on Twitter 1828938379830145484 Retweet on Twitter 1828938379830145484 1 Like on Twitter 1828938379830145484 14 Twitter 1828938379830145484
Load More

Copyright © 2024 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top